by lorenzgerber | Mar 21, 2022 | News
ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent...
by lorenzgerber | Feb 16, 2022 | News
SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology, today announced that it has signed a...
by lorenzgerber | Jun 29, 2021 | News
SINGAPORE and SAN DIEGO – June 29, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has made three strategic additions to its global team to expand the use...
by lorenzgerber | May 18, 2021 | Events
Michael Fehlings, PhD., ImmunoScape’s VP of Operations and Development, will be presenting on,”SARS-CoV-2 specific CD8+ T cell responses in convalescent COVID-19 individuals” on May 25 at 11:00-11:30 am PT. The CyTOF® Edge will be a half day virtual...
by lorenzgerber | May 4, 2021 | Events
ImmunoScape’s Senior Director of Business Development/Lead of the Vaccine Task Force, Dr. Brian Abel did a Bio Report podcast with Daniel Levine on Characterizing the Immunome at Scale discussing a collaborative study with National Institutes of Health’s...
